Novo Nordisk Competition -2.3% as GLP-1 Pressure Builds
Can Novo Nordisk Competition derail the obesity leader’s comeback before oral Wegovy and Medicare access have a chance to matter? Maik Kemper Editor in Chief Novo Nordisk A/S’s…
Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine? Maik Kemper Editor in Chief From my perspective, both…
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade? Maik Kemper Editor in Chief The oral Wegovy tablet…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite? Maik Kemper Editor in Chief Eli Lilly Orforglipron’s oral profile,…
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s sales? Maik Kemper Editor in Chief With the…
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave? Maik Kemper Editor in Chief Combination…
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik Kemper Editor in Chief “Collaboration with pharmaceutical companies…
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit cycle? Maik Kemper Editor in Chief 2026 is…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…